The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries, and is a critically important endeavour for the bleeding disorders community. Today, the World Federation of Hemophilia (WFH) and WFH USA are proud to announce that Roche has joined the WFH Humanitarian Aid Program.
The commitment of the Roche Group will consist of a donation of emicizumab, a prophylactic treatment for hemophilia A, and funding to deliver the WFH Humanitarian Aid Program’s integrated care development training to ensure that local infrastructure and medical expertise are available to use the donated emicizumab in the most efficient and effective way possible.
The donation will provide prophylactic treatment with emicizumab to as many as 1,000 people with hemophilia A in developing countries over the course of five years. The treatment focus will be on high-need patients, such as people with factor VIII inhibitors and children without factor VIII inhibitors. The Roche donation will bring prophylactic treatment—the standard of care for haemophilia A to prevent bleeds—to the developing world, which will have a significant impact on the local bleeding disorders communities in those countries.
Thanks to Roche’s donation, significantly more people with haemophilia A will be able to receive prophylaxis through the WFH Humanitarian Aid Program. Importantly, the donation will also provide a treatment option for people with hemophilia A with Factor VIII inhibitors who previously had very limited or no treatment. Increasing access to prophylactic treatments can make a profound difference in countries where hemophilia A remains underdiagnosed and untreated.
- Alain Weill, WFH President
This donation will provide those living with hemophilia A in the developing world unprecedented access to treatment. WFH recognizes Roche as a new contributor to the program, joining Bioverativ, a Sanofi company, and Sobi who contributed to the WFH program since 2015, as well as our contributors: Grifols, CSL Behring and GC Pharma.
To read the full press release, please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.